| Autor: |
Tabibzadeh A; Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran., Tameshkel FS; Student Research Committee, Iran University of Medical Sciences, Tehran, Iran.; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran., Moradi Y; Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran., Soltani S; Department of Virology, Tehran University of Medical Sciences, Tehran, Iran., Moradi-Lakeh M; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.; Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran., Ashrafi GH; Cancer Theme SEC Faculty, Kingston University, Penrhyn Road, London, KT1 2EE, UK., Motamed N; Department of Social Medicine, Zanjan University of Medical Sciences, Zanjan, Iran., Zamani F; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran., Motevalian SA; Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran., Panahi M; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran., Esghaei M; Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran., Ajdarkosh H; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran., Mousavi-Jarrahi A; School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Niya MHK; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran. karbalai.mh@iums.ac.ir. |
| Abstrakt: |
The present study was conducted to evaluate the prevalence of the signaling pathways mutation rate in the Gastrointestinal (GI) tract cancers in a systematic review and meta-analysis study. The study was performed based on the PRISMA criteria. Random models by confidence interval (CI: 95%) were used to calculate the pooled estimate of prevalence via Metaprop command. The pooled prevalence indices of signal transduction pathway mutations in gastric cancer, liver cancer, colorectal cancer, and pancreatic cancer were 5% (95% CI: 3-8%), 12% (95% CI: 8-18%), 17% (95% CI: 14-20%), and 20% (95% CI: 5-41%), respectively. Also, the mutation rates for Wnt pathway and MAPK pathway were calculated to be 23% (95% CI, 14-33%) and 20% (95% CI, 17-24%), respectively. Moreover, the most popular genes were APC (in Wnt pathway), KRAS (in MAPK pathway) and PIK3CA (in PI3K pathway) in the colorectal cancer, pancreatic cancer, and gastric cancer while they were beta-catenin and CTNNB1 in liver cancer. The most altered pathway was Wnt pathway followed by the MAPK pathway. In addition, pancreatic cancer was found to be higher under the pressure of mutation compared with others based on pooled prevalence analysis. Finally, APC mutations in colorectal cancer, KRAS in gastric cancer, and pancreatic cancer were mostly associated gene alterations. |
